Age-related Macular Degeneration Market Size, Share, Growth Analysis, By Drug Type(Aflibercept, Ranibizumab, and Others), By Disease Type(Wet Age-Related Macular Degeneration (AMD) and Dry Age-Related Macular Degeneration (AMD)), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35I2349 |
Region:
Global |
Published Date: October, 2024
Pages:
193
|Tables:
88
|Figures:
71
Age-related Macular Degeneration Market Insights
Global Age-related Macular Degeneration Market size was valued at USD 10.52 Billion in 2022 poised to grow from USD 11.24 Billion in 2023 to USD 19.18 Billion by 2031, growing at a CAGR of 6.9% in the forecast period (2024-2031).
Known as age-related macular degeneration (AMD), this slow progressing condition affects the eyes’ central part—the macula—connected with the retina. It causes damage to and eventually death of cells in macula leading to gradual loss of sight among elderly people. Two main types of the disease are usually identified: dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). Dry AMD is more common than wet AMD, which is rarer and leads to the growth of abnormal blood vessels underneath the macula.
To minimize dry AMD propensity treatments, include vitamin supplements together with changing one’s lifestyle to be healthier. Yet for wet AMD individuals need to go for injections directly into their eye preventing formation of peculiar veins leading to designing such medications. As for its working principle this sort of treatment is recognized as anti-VEGF or aberrant endothelial growth factor therapy involved in stopping any proteins that facilitate the creation of weird blood vessels. One important aspect behind loss in sight among elderly is the global age-related macular degeneration market. The senior population's increased use of medications for age-related macular degeneration (AMD) contributes to the market's growth. Take the rise in the number of people taking these medications.
Market Snapshot - (2024-2031)
Global Market Size
Largest Segment
Fastest Growth
Growth Rate
CAGR
To get more reports on the above market click here to Buy The Report
Age-related Macular Degeneration Market Segmental Analysis
The global age-related macular degeneration market is segmented based on Drug Type, Disease Type, Distribution Channel, Region. In terms of Drug Type, the market is trifurcated into Aflibercept, Ranibizumab and Others. Based on Disease Type, the market is bifurcated into Wet Age-Related Macular Degeneration (AMD) and Dry Age-Related Macular Degeneration (AMD). Based on the Distribution Channel, the market is trifurcated into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Region, the market is segmented into North America, Europe, Asia Pacific, Central & South America and Middle East & Africa.
Analysis by Drug Type
As per categorization by drug type, the market is classified as aflibercept, ranibizumab and others. Among these, aflibercept earned the largest share and continues to dominate the market. Aflibercept is a leading treatment for age-related macular degeneration (AMD) due to its potent angiogenesis inhibition and extended dosing intervals, enhancing patient compliance. Its dominance stems from clinical efficacy, reducing vision loss effectively, and offering superior outcomes over older therapies. Continuous advancements reinforce its pivotal role in AMD management.
Ranibizumab is expected to be the most rapidly expanding pharmaceutical agent in the global age-associated macular degeneration market due to its great efficiency in minimizing retinal destruction and shorter intervals of administration that enhance patients’ compliance. Furthermore, it has been proven through recent developments and clinical studies that it has better vision preserving ability than earlier medications. Also, its known safety record as well as present investigation of how best to utilize it have led to an increased acceptance and growth in AMD treatment arena.
Analysis by Disease Type
Wet AMD dominates the global market due to its severe impact on vision and high treatment demand. Innovations include advanced anti-VEGF therapies and novel gene therapies, improving efficacy and reducing treatment burden. Its prominence is driven by the urgent need for effective management of this aggressive form of AMD.
Dry AMD is set to be the fastest-growing segment in the global AMD market due to its higher prevalence and emerging treatment options. Therapeutic strategies have been innovatively enhanced by way of nutritional supplements and new pharmacotherapeutics which bear good fruits. The rapid growth is driven by increased awareness among the public and investment in research as new treatments hold a promise to delay progression and possibly restore sight. Thus, there’s a growing demand for effective dry AMD remedies, especially as the elderly population continues to increase.
To get detailed analysis on other segments, Request For Free Sample Report
Age-related Macular Degeneration Market Regional Insights
North America is ahead in the global age-related macular degeneration market as its healthcare system is advanced, it has a high prevalence rate of AMD and there are significant investments in research. In addition, the region enjoys established regulatory pathways which enable faster access to innovative treatments. Moreover, there are strong awareness programs and high health care expenditures that support the wide use of advanced therapies. The presence of leading pharmaceutical companies and clinical trial hubs in North America further supports its dominance. The growing aging population and increasing incidence of AMD in this region drive continuous demand for effective treatment solutions, reinforcing North America's market leadership.
The fastest growing region of world in the global age-related macular degeneration market is Asia-Pacific owing to rapid urbanization, increasing aging population and rising healthcare investments. Improved economic growth provides better access to advanced medicines for ocular diseases like AMTs while the increasing awareness about them drives demand for effective therapies. This region has a huge number of AMD patients and there has been significant investment in research and development which promotes expansion of this sector. Moreover, having established collaborations with globally recognized pharmaceutical corporations, local partners now foster an increase in accessibility and cost-friendly approaches to age-related macular degeneration medication which stimulates fast growth within the Asia-Pacific region’s market whilst at the same time responding to healthcare demands that arise across a vast territory.
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Age-related Macular Degeneration Market Dynamics
Drivers
Rising Aging Population
- Increased elderly population being susceptible to AMD is driving the global age-related macular degeneration market. The longer people live, the more they are exposed to its risk which leads in turn to requests for AMD therapies and treatments so as to manage and stop sight loss.
Advancements in Treatment Options:
- The proliferation of the market due to the novel anti-VEGF medicines and up-and-coming gene therapies are some of the innovations in AMD treatments. With better treatment effectiveness and longer drug intervals, health results for patients improve, which causes an increase in utilization rates thereby enhancing the potential for more expansion in the sector.
Restraints
Lack of Early Diagnosis
- Screening and diagnostics for AMD are not enough in some places until you have a look at how it impacts everything else such as poor outcomes and treatment delays. The lack of information about available diagnostic tools also limits market growth as individuals tend to get late interventions and this reduces the efficiency of existing therapies.
Limited Reimbursement Coverage
- The progression of the market can be affected by the variable policies for reimbursement and coverage of treatments related to AMD. Patients may avoid seeking treatment if their insurance does not cover it, or this may limit the use of newer therapy types altogether. This will ultimately affect Market Growth and Access.
Request Free Customization of this report to help us to meet your business objectives.
Age-related Macular Degeneration Market Competitive Landscape
The competitive global age-related macular degeneration market denotes that a host of various pharmaceutical companies struggle to capture market share with their new therapies. Novartis’ Lucentis is one of the key anti-VEGF drugs while Eylea, developed by Regeneron Pharmaceuticals, stands out. To mention but a few Roche’s Avastin is part of key players in this field. They work hard developing advanced treatment modalities meant at ensuring better patient outcomes and filling any existing gap in terms of successful therapies. Thereby competition enhances ongoing innovations, which consequently leads to more effective treatments being available for AMD patients globally.
Top Player’s Company Profiles
- Novartis (Switzerland)
- Regeneron Pharmaceuticals (USA)
- Roche (Switzerland)
- Bayer (Germany)
- Allergan (USA)
- Pfizer (USA)
- AbbVie (USA)
- Apellis Pharmaceuticals (USA)
- Stealth BioTherapeutics (USA)
- Iveric Bio (USA)
- Kymab (UK)
- Ophthotech Corporation (USA)
- Zymeworks (Canada)
- Galderma (Switzerland)
- EyePoint Pharmaceuticals (USA)
Recent Developments
- In September 2024, The FDA has just approved a new AMD therapy called Beovu by Novartis. As such, the dosing regime is less frequent than other currently available therapies for AMD leading to an improved patient adherence and effective vision preservation. In so doing, periodic reminders of Novartis's aims to advance care for AMD patients are provided with better results.
- In July 2024, Lenchite, the pharmaceutical company Regeneron unveiled good Phase III results for Eylea that is used together with other drugs to treat AMD. The results show better sight conditions and longer intervals between treatments. The data shows that vision outcomes are better, and treatment intervals can be increased. This development highlights Regeneron's ongoing efforts to enhance treatment efficacy and provide more flexible options for managing wet AMD.
- In August 2024, Apellis Pharmaceuticals launched Empaveli, a novel treatment for dry AMD. This breakthrough therapy targets complement pathway inhibition, addressing a significant unmet need in dry AMD management. The launch marks a significant milestone in Apellis’s strategy to provide innovative solutions for chronic retinal diseases.
Age-related Macular Degeneration Key Market Trends
- Emergence of Long-Acting Therapies: In the AMD market there is an increasing trend towards long-action therapies like anti-VEGF treatments of extended duration. These innovations help in reducing the number of times patients need to be injected, hence improving their compliance and results; thus, fueling growth within the market that has had its challenges with earlier treatments.
- Rising Focus on Personalized Medicine: The treatment methods in AMD are increasingly personalized, based on knowledge of genetics and biomarkers to customize therapies to fit the individual patients’ profiles best. It aims at improving efficacy and minimizing the adverse effects on patients so that there may be more targeted and efficient management techniques for AMD.
Age-related Macular Degeneration Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, there have been remarkable progressions in the global age-related macular degeneration market regarding treatment modalities because of an increasing elderly populace as well as inventive pharmaceuticals. Although wet AMD still takes precedence due to its gravity, dry AMD is exponentially expanding due to new therapeutics targeting higher incidence rates.
North America governs the market owing to what it has in terms of a solid healthcare infrastructure, whereas the fastest growth is realized in the Asia-Pacific region due to urbanization and also investment in healthcare. Despite the challenges of high treatment costs and regulatory hurdles, the AMD treatment landscape is constantly shaped by ongoing research and market dynamics.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 10.52 Billion |
| Market size value in 2031 | USD 19.18 Billion |
| Growth Rate | 6.9% |
| Base year | 2023 |
| Forecast period | (2024-2031) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Age-related Macular Degeneration Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Age-related Macular Degeneration Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Age-related Macular Degeneration Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Age-related Macular Degeneration Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Age-related Macular Degeneration Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Age-related Macular Degeneration Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
